IBM helps Celgene monitor drug reactions
IBM is working with New Jersey-based Celgene to enhance pharmacovigilance methods used to collect, assess, monitor and report adverse drug reactions. The offering will run on the Watson Health Cloud.
The collaboration will combine Watson's cognitive computing ability with Celgene's deep history and experience in drug safety and risk management to create an outcome- and evidence-based drug safety decision support system for life science companies.
Watson's cognitive computing engine continuously learns, so it is expected that Watson for Patient Safety will increasingly be able to help identify potential drug safety signals. It is being developed as a first-of-its-kind, automated drug-safety offering designed to enable the collection, collation and automated analysis of high volumes of data from diverse sources, including anonymised electronic medical records, medical claims databases and other healthcare information sources.
"With this collaboration, we intend to create a paradigm shift in identifying patient safety data that we hope can be applied across the entire product lifecycle from early development through to approved medicines," said John Freeman, corporate vice president at Celgene. "The new offering we are co-developing will bring the cognitive computing power of Watson and its growing view of clinical, research and social health data to bear on this critical healthcare challenge."
The system will be designed to drive pharmaceutical companies' understanding of complex safety questions, and delivery of evidence-based insights to help support on-going understanding of the safety profiles of drug products by stakeholders. This approach is intended to help biopharmaceutical companies and other stakeholders better manage and interpret large volumes of individual case safety reports describing potential side effects associated with drug products.
Across the biopharmaceutical industry these reports are increasing in volume and complexity as data sources grow and regulations evolve.
"Celgene established one of the first risk management systems, and its commitment to pharmacovigilance continues with this collaboration," said Lauren O'Donnell, vice president of life sciences at IBM Watson Health. "Together we look forward to creating a cognitive solution that can be applied across the industry to help benefit patients everywhere, leveraging our cloud platform."
Watson for Patient Safety will be developed in phases, with the first module anticipated within the next year. Watson Health Cloud provides a health-data enabled infrastructure and is designed to streamline GxP compliance.
Celgene, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialisation of therapies for the treatment of cancer and inflammatory diseases through developments in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.